It could double the size of the cholesterol drug market to 70 million people.
No surprise there: the European prescription-drug market accounts for a third of worldwide drug sales.
ECONOMIST: Let advertisers tell Europe��s patients more about drugs
It appears that the overall immunology drug market is increasing and international markets present a large growth opportunity.
FORBES: Johnson & Johnson's Earnings Buoyed By Pharma Strength
The new discipline could change the drug market by reducing the rate of product failure in clinical trials.
Owing to these factors, the global diabetes drug market has seen rapid growth rate in the last couple of years.
FORBES: Johnson & Johnson's Earnings Buoyed By Pharma Strength
Novartis is looking to enter the arthritis drug market with its own version of a widely successful class of painkiller.
It is by far the largest generic drug market in Latin America, and has a lot of room to grow.
No firm currently has more than about 5% of the world's drug market, but some aspire to dominate particular diseases.
The decision leaves Pfizer without anything in the highly lucrative cholesterol-drug market to replace Lipitor when its patent expires in 2010.
The emerging results could throw the colon cancer drug market in turmoil.
Novartis has 12% of the cancer drug market and is trying to keep pace with its cross-town rival Roche, the biggest seller of targeted cancer drugs.
The compound annual growth rate of the orphan drug market between 2001 and 2010 was 25.8 percent, compared with 20.1 percent for a matched control group of non-orphan drugs.
Novartis is embracing a generic-drug market that has ballooned in the past few years as health-care providers have sought to put a brake on the ever-rising costs of treatment.
The barriers for companies to enter the rare-disease drug market are already high, he says, and families don't want to make it even more difficult by arguing over natural-history studies.
Earlier in January, Merck Chief Executive RichardClarkRichard Clark said he expected Vytorin to keep a secure position in the cholesterol drug market and cited several other ongoing studies in addition to this one.
Earlier in January, Merck Chief Executive Richard Clark said he expected Vytorin to keep a secure position in the cholesterol drug market and cited several other ongoing studies in addition to this one.
Because many drug makers talk so much about emerging markets, and because prominent companies (Pfizer) are going to see U.S. sales contract, it is easy to forget that the U.S. drug market is still huge.
Many biotech watchers expect the hepatitis C market to follow a similar trajectory as the HIV drug market, where breakthrough first-generation drugs were relatively quickly supplanted by more convenient second-generation versions with fewer side effects.
The good data caught the attention of Berlin-based Schering AG, the leader in the MRI contrast drug market, which signed up to make MS-325 and combine its own MRI research operations with those of Epix in a joint venture.
The company has tried to create new enthusiasm with with efforts to expand into hepatitis C, the viral liver disease that is looking like the next big drug market, and into other areas such as heart disease, cystic fibrosis, and pulmonary arterial hypertension.
FORBES: Gilead Tries To Revive Itself With $11 Billion Purchase Of Pharmasset
Bristol was merely getting the right to be first to bring the drug to market.
He declines to say which of those he'll use to get his drug to market.
The company argues that it may have some options for getting the drug to market soon.
The costs of bringing a new drug to market run into the hundreds of millions of dollars.
Pharmacia now has a green light from the U.S. Food and Drug Administration to market a new hypertension drug.
If the drug gains FDA approval, Englander will have to decide whether or not ID Biomedical can bring the drug to market without getting crushed by larger competitors.
Unlike the case with Zetia and Vytorin, Merck will pocket all the profits from Cordaptive, so the company might not mind if its new drug steals market share from its old ones.
The tough path to getting a drug to market was demonstrated Monday, as Pfizer Inc. said a highly anticipated potential treatment for Alzheimer's failed to reach its goals in a Phase 3 study.
WSJ: 'Medical Foods' and Supplements for Brain Health Advance
These inhibitors represent a totally new way to lower LDL cholesterol and many companies are racing to bring such a drug to market including Amgen (AMGN), Pfizer (PFE), Roche and Lilly (LLY).
Although AtheroGenics chief RussellMedfordRussell Medford says he is exploring faster methods for getting the drug to market, most expect that another multiyear trial will have to be conducted at a cost of tens of millions of dollars.
应用推荐